Active Ingredient(s): Samarium-153 Lexidronam
FDA Approved: * March 28, 1997
Pharm Company: * CYTOGEN
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Quadramet Overview

Samarium (153Sm) lexidronam (chemical name Samarium-153-ethylene diamine tetramethylene phosphonate, abbreviated Samarium-153 EDTMP, trade name Quadramet) is a chelated complex of a radioisotope of the element samarium with EDTMP. It is used to treat pain when cancer has spread to the bone.[1][2] It is injected into a vein and distributed throughout the body, where it is preferentially absorbed in areas where cancer has invaded the bone. The radioisotope 153Sm...

Read more Quadramet Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Samarium_(153Sm)_lexidronam

Recent Quadramet Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Samarium-153 Lexidronam
  • Injection: 50mCi/ml, 50unit/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Quadramet: (2 results)

Sorted by National Drug Code
  • 11994-016 Quadramet 50 mci/Ml Intravenous Injection, Solution by Lantheus Medical Imaging, Inc.
  • 57902-860 Quadramet 50 mci/Ml Intravenous Injection, Solution by Jazz Pharmaceuticals, Inc.

Other drugs which contain Samarium-153 Lexidronam or a similar ingredient: (1 result)